MBRX - Moleculin Biotech, Inc.
| Previous Close | 1.0800 |
| Open | 1.0900 |
| Bid | 1.1100 x 1400 |
| Ask | 1.1600 x 1100 |
| Day's Range | 1.0600 - 1.1000 |
| 52 Week Range | 0.7770 - 3.1500 |
| Volume | 98,939 |
| Avg. Volume | 412,793 |
| Market Cap | 47.904M |
| Beta (3Y Monthly) | 2.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5120 |
| Earnings Date | Nov 11, 2019 - Nov 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- PR Newswire
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019
HOUSTON, Aug. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second quarter ended June 30, 2019. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, chairman and chief executive officer of Moleculin, said, "The second quarter of 2019 exhibited significant progress in the various research initiatives and clinical trials that are underway on our drug candidates.
- Zacks
Moleculin Completes Enrollment in Early-Stage Cancer Study
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
- PR Newswire
Moleculin Announces Completion of Lymphoma Trial Enrollment
HOUSTON, Aug. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its proof of concept clinical trial to evaluate its p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment. "We believe there continues to be an unmet need for an improved topical therapy for Stage I-III CTCL skin lesions," commented Walter Klemp, Moleculin's Chairman and CEO, "especially one that may avoid significant unwanted side effects.
- PR Newswire
Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models
HOUSTON, Aug. 6, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a paper entitled "Immunological Reprogramming in the CNS Tumor Microenvironment and Therapeutic Efficacy of Radiotherapy with STAT3 Blockade" will be presented at the Inaugural Conference on Brain Metastases, in New York City, August 16-17, 2019.
- Benzinga
Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort
Moleculin Biotech Inc (NASDAQ: MBRX) announced positive data Thursday from its Phase 1/2 study of annamycin in Poland. Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer. The company said intends to advance the clinical study of Annamycin to the next dose level.
- PR Newswire
Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort
HOUSTON, July 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. Three patients were treated at dose level of 150 mg/m2 with no drug-related adverse events, including no signs of cardiotoxicity.
- Zacks
Moleculin Files New Patents for Cancer Candidate Annamycin
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
- Benzinga
Moleculin Rallies On Patent Applications That Could Give Cancer Drug 20 Years of Protection
Moleculin Biotech Inc (NASDAQ: MBRX )'s stock was advancing Wednesday on heavy volume. Moleculin, which focuses on drugs targeting highly resistant tumors, said it has filed new patents covering the production ...
- PR Newswire
Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation
HOUSTON, July 10, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML).
- Simply Wall St.
What Type Of Shareholder Owns Moleculin Biotech, Inc.'s (NASDAQ:MBRX)?
If you want to know who really controls Moleculin Biotech, Inc. (NASDAQ:MBRX), then you'll have to look at the makeup...
- PR Newswire
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019
HOUSTON, May 14, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the first quarter ended March 31, 2019. Additionally, the Company announced potential upcoming milestones and recent corporate developments. This time last year we had just commenced our first clinical trial for one drug. Today, we have three drugs in four clinical trials under way with a fifth clinical trial that may start before year end.
- PR Newswire
Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe
2 of 3 patients qualify to proceed to a potentially curative bone marrow transplant; trial advances to next higher dose level HOUSTON , May 7, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ...
- PR Newswire
Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans
Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has scheduled an investor conference call for May 15, 2019 with Joseph Moscato, President & Chief Executive Officer of Generex who will present an organizational roadmap outlining Generex Biotechnology's operational, strategic and financial plans, as outlined herein.
CNW GroupPositive Results From HMN Lithium Project P.E.A.
Positive Results From HMN Lithium Project P.E.A.
- PR Newswire
US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment
Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts. HOUSTON, April 29, 2019 /PRNewswire/ -- A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland, speeding the process of patient recruitment and data collection. The company, Moleculin (MBRX), recently recruited 3 patients in 6 weeks in Poland, whereas in the U.S. it took a full year to build a similar, complete cohort.
- PR Newswire
Moleculin Announces $15.0 Million Registered Direct Offering
HOUSTON, April 23, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. The offering is expected to close on or about April 25, 2019, subject to customary closing conditions. The gross proceeds of the offering are expected to be approximately $15.0 million, prior to deducting the placement agent fees and other estimated offering expenses.
- Benzinga
The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...
- PR Newswire
Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019
HOUSTON , April 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug ...
- PR Newswire
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin
HOUSTON, April 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the U.S. Food and Drug Administration ("FDA") has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia ("AML").
- PR Newswire
Moleculin Announces Significant Discovery in Lung Cancer Models
"We know that Annamycin was previously shown to be significantly more potent than doxorubicin in both Lewis lung carcinoma in vivo and small cell lung cancer in vitro models," commented Walter Klemp, Moleculin's Chairman and CEO. "Now we are seeing significant activity against triple negative breast cancer that has metastasized to the lungs.
- PR Newswire
Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial
HOUSTON, April 11, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors. "Given the exciting data Emory University researchers presented at the recent Society for Neuro Oncology conference, we have been working closely with them to begin a trial in pediatric brain tumors," commented Walter Klemp, Moleculin's Chairman and CEO. This will also give us yet another opportunity to develop human proof of concept data, bringing our total number of clinical trials to five.
- PR Newswire
Moleculin Announces Successful Expansion of its Leukemia Drug Program
HOUSTON, April 9, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. (www.bsppharmaceuticals.com) in Latina, Italy. "Securing production supply for a liposomal anthracycline like Annamycin is no trivial matter, which is why we partnered last year with a quality supplier like BSP, who will be able to supply Annamycin in commercial quantities going forward," commented Walter Klemp, Moleculin's Chairman and CEO.
- PR Newswire
Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting
The presentation included data resulting from preclinical evaluation in pancreatic cancer models of STAT3 inhibitors WP1066 and WP1732, both discovered at The University of Texas MD Anderson Cancer Center and licensed by Moleculin. WP1066 is an orally bioavailable drug with significant brain uptake that is currently in Phase I clinical studies in patients with brain tumors.
- PR Newswire
EnerCube Completes Complex Design Project With Altasteel
TORONTO, April 1, 2019 /PRNewswire/ -- CellCube Energy Storage Systems Inc. ("CellCube" or the "Company") (CSE CUBE) (CUBE.CN) (CECBF) (Frankfurt 01X, WKN A2JMGP) on behalf of its wholly-owned subsidiary, EnerCube Switchgear Systems Inc. ("EnerCube") is pleased to announce EnerCube has completed a significant sale and complex switchgear upgrade to the AltaSteel plant. AltaSteel is a Canadian manufacturer of prime quality steel products for the mining, construction, automotive and engineering industries based in Edmonton, Alberta.
- PR Newswire
Moleculin Announces Pricing Of Underwritten Public Offering
HOUSTON, March 27, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the pricing of an underwritten public offering of an aggregate of 5,250,000 units at a public offering price of $1.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 5,250,000 shares of common stock and warrants to purchase 2,625,000 shares of common stock.
